Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics-Reference-Cited by-同舟云学术

Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics

Published:2019-06-19 Issue:497 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

McAleer Christopher W.¹^ORCID,Long Christopher J.¹^ORCID,Elbrecht Daniel¹^ORCID,Sasserath Trevor¹,Bridges L. Richard¹^ORCID,Rumsey John W.¹^ORCID,Martin Candace²,Schnepper Mark²,Wang Ying²^ORCID,Schuler Franz³,Roth Adrian B.³^ORCID,Funk Christoph³,Shuler Michael L.¹^ORCID,Hickman James J.¹²^ORCID

Affiliation:

1. Hesperos Inc., 3259 Progress Drive, Room 158, Orlando, FL 32826, USA.

2. NanoScience Technology Center, University of Central Florida, 12424 Research Parkway, Suite 400, Orlando, FL 32826, USA.

3. Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann–La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.

Abstract

An in vitro multi-organ system evaluates the efficacy and potential off-target toxicities of anticancer parent drugs and metabolites.

Funder

National Institutes of Health

Hoffman-La Roche

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference51 articles.

1. Rapidly rising clinical trial costs worry researchers

2. The price of innovation: new estimates of drug development costs